CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $825.37M, above the global median of $520.53M
- FinancialsAltman Z-Score 1.12: grey zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
468.08MUSDvs all stocks (USD)
Revenue (TTM)
825.37MUSDvs all stocks (USD)
Profit Margin
-7.27%vs Medical Devices peers
Beta
0.7120xvs all stocks
52-Week Change
8.53%vs all stocks
Market Capitalization
468.08MUSDvs all stocks (USD)
Enterprise Value
610.06MUSDvs all stocks (USD)
Forward P/E
13.79xvs Medical Devices peers
Price to Sales (TTM)
0.5671xvs Medical Devices peers
Price to Book (MRQ)
1.07xvs Medical Devices peers
Enterprise to Revenue
0.7390xvs Medical Devices peers
Enterprise to EBITDA
35.88xvs Medical Devices peers
Gross Margin
70.94%vs Medical Devices peers
Profit Margin
-7.27%vs Medical Devices peers
Operating Margin
-6.75%vs Medical Devices peers
Return on Assets (TTM)
-3.25%vs Medical Devices peers
Return on Equity (TTM)
-13.43%vs Medical Devices peers
Revenue (TTM)
825.37MUSDvs all stocks (USD)
Revenue per Share (TTM)
20.68USDUpdated Jul 19, 2026Quarterly Revenue Growth
1.60%vs Medical Devices peers
Gross Profit (TTM)
586.10MUSDvs all stocks (USD)
EBITDA (TTM)
8.79MUSDvs all stocks (USD)
Net Income (TTM)
-60.01MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
1.58%vs Medical Devices peers
Operating Cash Flow (TTM)
34.13MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
22.02MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
822.31MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
256.30MUSDFY2025 · Dec 31, 2025Gross Profit
566.02MUSDFY2025 · Dec 31, 2025Operating Income
-82.57MUSDvs all stocks (USD)
Pre-tax Income
-90.81MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.38MUSDFY2025 · Dec 31, 2025Net Income
-92.19MUSDFY2025 · Dec 31, 2025EBIT
-73.32MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
8.79MUSDFY2025 · Dec 31, 2025Research & Development
65.85MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
554.33MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
17.49MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.33USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.33USDFY2025 · Dec 31, 2025Basic Shares Outstanding
39.60MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
39.60MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-92.19MUSDFY2025 · Dec 31, 2025Operating Cash Flow
3.05MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
85.11MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-92.19MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
83.25MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
223.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
28.69MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-690.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.58MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.60MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-17.25MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Other Investing Activity
28.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
28.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-762.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-5.95MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-786.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
40.38MSharesUpdated Jul 19, 2026Float Shares
40.10MSharesUpdated Jul 19, 2026Shares Short
2.36MSharesUpdated Jul 19, 2026Short Ratio
5.44daysvs all stocks
Short % of Shares Outstanding
6.61%vs all stocks
% Held by Insiders
2.19%vs all stocks
% Held by Institutions
91.97%vs all stocks
Total Cash (MRQ)
120.28MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.98USDUpdated Jul 19, 2026Total Debt (MRQ)
262.26MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6026xvs Medical Devices peers
Current Ratio (MRQ)
2.87xvs Medical Devices peers
Book Value per Share (MRQ)
10.78USDUpdated Jul 19, 2026Total Assets
850.65MUSDvs all stocks (USD)
Total Current Assets
416.85MUSDFY2025 · Dec 31, 2025Total Liabilities
400.61MUSDFY2025 · Dec 31, 2025Total Non-current Assets
433.80MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
230.13MUSDFY2025 · Dec 31, 2025Total Current Liabilities
170.48MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
82.03MUSDFY2025 · Dec 31, 2025Accounts Receivable
135.75MUSDFY2025 · Dec 31, 2025Inventory
172.32MUSDFY2025 · Dec 31, 2025Accounts Payable
58.39MUSDFY2025 · Dec 31, 2025Short-term Debt
3.98MUSDFY2025 · Dec 31, 2025Other Current Liabilities
4.29MUSDFY2025 · Dec 31, 2025Long-term Debt
174.45MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
55.68MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.98MUSDFY2025 · Dec 31, 2025Retained Earnings
-368.33MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
450.04MUSDvs all stocks (USD)
52-Week Low
8.85USDUpdated Jul 19, 202652-Week High
16.99USDUpdated Jul 19, 202652-Week Change
8.53%vs all stocks
Beta
0.7120xvs all stocks
50-Day MA
10.52USDUpdated Jul 19, 2026200-Day MA
13.08USDUpdated Jul 19, 2026Avg 10-Day Volume
376.62KSharesUpdated Jul 19, 2026Avg 30-Day Volume
401.83KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.50USDUpdated Jul 19, 2026Other Income / Expense
9.25MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Depreciation-Heavy Reported Profit
It reports a profit, and much of the gap to cash is depreciation rather than earnings.
Reads
Diagnostic
Earnings Growth With Heavy Accrual Component
It reports a profit, with depreciation heavy in the cash bridge and receivables rising.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.71Profit Margin: -0.07
Financial Health
Altman Z-Score 1.12: grey zoneSignificant
Altman Z-Score: 1.12
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $825.37M, above the global median of $520.53MNotable
Revenue (USD): 825,374,016Global Median: 520,528,949.311
Levered free cash flow is $22.02M, above the global median of $16.24MNotable
Levered free cash flow (USD): 22,024,250Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Baolingbao Biology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlow
Jiangsu Hanbon Science & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Leadman Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yungshin Global Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jenscare Scientific Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Kawin Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cabaletta Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ocugen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Fengyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Anhui Sunhere Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Alignment Healthcare, Inc.
3 interpretationsDepreciation-Heavy Reported ProfitEarnings Growth With Heavy Accrual ComponentRevenue Growing With Receivables Growing
Molina Healthcare Inc.
3 interpretationsDepreciation-Heavy Reported ProfitEarnings Growth With Heavy Accrual ComponentRevenue Growing With Receivables Growing
Grid Dynamics Holdings, Inc.
3 interpretationsDepreciation-Heavy Reported ProfitEarnings Growth With Heavy Accrual ComponentRevenue Growing With Receivables Growing